Pfizer (PFE)

26.26
+0.00 (0.00%)
NYSE · Last Trade: Apr 30th, 9:19 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close26.26
Open-
Bid26.35
Ask26.39
Day's RangeN/A - N/A
52 Week Range21.97 - 28.75
Volume1,742,457
Market Cap147.23B
PE Ratio (TTM)19.31
EPS (TTM)1.4
Dividend & Yield1.720 (6.55%)
1 Month Average Volume35,060,635

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?fool.com
This particular player has seen its yield rise in recent years.
Via The Motley Fool · April 30, 2026
Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Studybenzinga.com
Pfizer reports Phase 3 data showing ELREXFIO improved progression-free survival versus standard therapy in multiple myeloma study.
Via Benzinga · April 29, 2026
Do Wall Street Analysts Like Bristol-Myers Squibb Stock?
Although Bristol-Myers Squibb has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Via Barchart.com · April 29, 2026
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression‑free survival (PFS), as assessed by blinded independent central review (BICR), versus standard-of-care daratumumab plus pomalidomide and dexamethasone (DPd). The safety and tolerability of ELREXFIO was consistent with its known safety profile.
By Pfizer Inc. · Via Business Wire · April 29, 2026
2 High-Yielding Dividend Stocks to Buy for Passive Income in Aprilfool.com
It's still time to pick up their shares on the dip.
Via The Motley Fool · April 28, 2026
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session.chartmill.com
Via Chartmill · April 28, 2026
Should You Buy, Sell, or Hold Pfizer at $27?fool.com
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark.
Via The Motley Fool · April 28, 2026
Pfizer Reaches Three Settlement Agreements for VYNDAMAX
Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.S. District Court for the District of Delaware for infringement of patents relating to VYNDAMAX® (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). These settlements extend the effective U.S. patent expiry date for VYNDAMAX to June 1, 2031, subject to the outcome of other litigation. Pfizer had previously anticipated a significant decline in U.S. revenues for VYNDAMAX beginning in 2029 upon patent expiry. As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031.
By Pfizer Inc. · Via Business Wire · April 28, 2026
Are Wall Street Analysts Bullish on Pfizer Stock?
Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.
Via Barchart.com · April 28, 2026
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Dealfool.com
Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus.
Via The Motley Fool · April 27, 2026
Is Bristol Myers Squibb the Best Bargain in Big Pharma?fool.com
This pharma stock is cheap for a reason.
Via The Motley Fool · April 27, 2026
VCIT vs. IEI Comes Down to What Job Your Bond Sleeve Is Doingfool.com
Explore how differences in bond type, risk, and income potential set these two popular ETFs apart for investors.
Via The Motley Fool · April 25, 2026
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom?fool.com
The weight loss drug market may reach almost $100 billion in a few years.
Via The Motley Fool · April 25, 2026
Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know.fool.com
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.
Via The Motley Fool · April 25, 2026
These S&P500 stocks are the most active in today's sessionchartmill.com
Via Chartmill · April 24, 2026
Unusual Put Activity Is Flagging a Smart Trade Setup in This New Quantum Computing Stock
Quantum computing firm Infleqtion led Thursday with a 133.59 Vol/OI ratio. The Jan. 15/2027 $10 put made up 23% of volume, which was 2.8 times its 30-day average, making the trade sneaky smart. Here’s why.
Via Barchart.com · April 24, 2026
Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.
A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.
Via Barchart.com · April 24, 2026
Pfizer Declares Second-Quarter 2026 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company’s common stock, payable June 12, 2026, to holders of the Common Stock of record at the close of business on May 8, 2026. The second-quarter 2026 cash dividend will be the 350th consecutive quarterly dividend paid by Pfizer.
By Pfizer Inc. · Via Business Wire · April 22, 2026
Should You Forget Pfizer and Buy This Pharma Stock Instead?fool.com
Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?
Via The Motley Fool · April 22, 2026
Why Merck (MRK) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
Via StockStory · April 21, 2026
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopolyfool.com
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.
Via The Motley Fool · April 21, 2026
This Drug Stock Has Crushed the S&P 500 Over the Last Decadefool.com
Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.
Via The Motley Fool · April 18, 2026
Where Will Pfizer Stock Be in 3 Years?fool.com
The healthcare giant has been investing heavily in its future growth.
Via The Motley Fool · April 18, 2026
Better Long-Term Buy: Eli Lilly or Viking Therapeutics?fool.com
One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.
Via The Motley Fool · April 17, 2026
2 Value Stocks to Research Further and 1 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via StockStory · April 17, 2026